Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Overview

The rheumatoid arthritis market, valued at USD 27.8 billion in 2024, is projected to reach USD 28.8 billion in 2025 and USD 40.1 billion by 2035, representing a CAGR of 3.4% during the forecast period. Rheumatoid Arthritis (RA) is an autoimmune, inflammatory disorder wherein various components of the immune system begin to attack the body’s own cells and tissues. The disease is characterized by pain and swelling in and around the joints. It is a systemic disease and is known to affect several joints at the same time or different joints at different times. Hence, it is also termed as migratory or flitting polyarthritis. It has been estimated that RA affects over 1% of the world population and the overall risk of developing the disease is higher in women as compared to men.

Owing to the complex nature of the disease, there is no cure for RA yet. However, in the past few years, several synthetic and biological treatments have been designed to achieve minimum disease activity, decrease inflammation and pain, prevent joint damage and reduce the pace of disease progression. Treatment strategies have evolved from the use of salicylates to non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, synthetic disease modifying anti rheumatoid drug (DMARDS), such as methotrexate (MTX), sulfasalazine and leflunomide, and gradually to biologic response modifiers. MTX, one of the most popular synthetic DMARDs used to treat RA, was approved in 1988 and is generally used as a first line therapy. However, due to certain side-effects associated with treatment regimens involving higher doses of synthetic DMARDs and the fact that some patients fail to respond to such RA drugs have led to a shift in the market towards biologic therapies. The transition to biologic DMARDs has brought a significant change in rheumatoid arthritis market. Biologics are a more targeted therapeutic option and result in significant reduction in disease symptoms and a decrease in disease activity in a large proportion of RA patients. Despite the known advantages, a subset of patients treated with biologics demonstrated the need of more innovative options, thereby prompting the drug developers to look for alternative therapeutic strategies.

Several biopharmaceutical companies have been active in this area since last few years while others have recently stepped in. Apart from focusing on already established mechanisms of action, these companies are trying to offer novel and innovative treatment options. A number of collaborations and partnerships have been inked between various companies to progress the R&D and commercialization activities. As more such new generation molecules reach the late stages of clinical development and eventually get commercialized, the rheumatoid arthritis market is likely to witness substantial market growth during the forecast period.

Recent Developments in Rheumatoid Arthritis Market:

Several recent developments have taken place in the field of rheumatoid arthritis market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In August 2023, Taisho Pharmaceutical received the FDA approval to manufacture and commercialize Nanozora® 30 mg autoinjector which will be used for the treatment of patients suffering from rheumatoid arthritis. 
• In July 2023, Arthritis Foundation and CARRA raised USD 1.2 million with an aim to address research gaps in pediatric rheumatology. 
• In April 2023, Jubilant Therapeutics published data on orally administered PAD4 inhibitor activity in rheumatoid arthritis preclinical models.

Scope of the Report

The “Rheumatoid Arthritis Market, Till 2035” report provides a comprehensive analysis of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the rheumatoid arthritis market. RA is known to substantially affect patients’ quality of life and is characterized by a more severe set of symptoms than those observed in patients with osteoarthritis.

The rheumatoid arthritis market is primarily populated by DMARDs that have been shown to alter the course of the disease and also improve radiographic outcomes. Biologic DMARDs including TNF inhibitors, such as HUMIRA® (USD 14 billion) , Enbrel® (USD 9 billion), and REMICADE® (USD 6.6 billion), are counted among the best-selling anti arthritis drugs in this market. In recent years, treatment options for RA have increased substantially with the development of several novel rheumatoid arthritis drugs / drug classes. In addition to TNF inhibitors, a number of novel biologic DMARDs, such as T-cell costimulatory blocking agents (Orencia®), B-cell depleting agents (Rituxan®), interleukin-6 (IL-6) inhibitors (Actemra®) and interleukin-1 (IL-1) receptor antagonists (Kineret®), have been approved over the past few years. 

In 2012, Xeljanz®, the first oral non-biologic DMARD belonging to the janus kinase (JAK) inhibitors drug class was approved in the US. The drug generated revenues worth USD 523 million in 2015 alone. In comparison to traditional biologic DMARDs, which are delivered through injections or infusions, JAK inhibitors, or Jakinibs, are a new class of RA drugs that have been optimized for oral delivery. It is also worth mentioning that a number of pharmaceutical companies are developing anti arthritis drugs with novel mechanisms of action, namely Bruton's tyrosine kinase (BTK) inhibitors, spleen tyrosine kinase (SYK) inhibitors, RANKL inhibitors and adenosine A3 receptor (A3AR) agonists, which (along with Jakinibs) represent the next generation of rheumatoid arthritis drugs designed to treat RA. During the course of our study, we identified over 80 non-TNF inhibitors that are either already marketed or in various phases of development for the treatment of RA; of these, five RA drugs are currently marketed and four drugs (a JAK inhibitor, a RANKL inhibitor and two IL-6R inhibitors) are in the pre-registration stage. Overall, more than 60% of candidate RA drugs are currently under clinical development. Drug development efforts in rheumatoid arthritis market are being actively led by a mix of pharmaceutical giants, mid-sized companies and start-ups. Among other things, the market research report features discussions on:

• The current state of the market with respect to available drug classes, key players, phase of development of pipeline products (clinical and preclinical / discovery), route of administration, type of molecule and type of therapy.
• An in-depth analysis comprising of schematic representations, including a grid analysis highlighting the distribution of pipeline, an overview of the landscape of industrial developers (small, mid-sized and large players) and the geographical distribution of the companies involved in the development of RA therapeutics.
• Detailed profiles of drugs that have been recently (post-2010) approved / marketed or are in the late stages of development (phase III and above).
• Information on the mechanisms of action of novel drugs (non-TNF inhibitor) that are currently being investigated as potential treatment options for RA.
• Detailed comparative analysis of the key clinical trial endpoints for drugs that are already marketed or are in phase III of development and insights on the clinical development programs designed for phase III drugs (active comparator trials, important primary endpoints and scale of trials).
• A detailed analysis of the collaborations and agreements established amongst stakeholders in the past few years.
• Emerging trends and a discussion on the popularity of non-TNF inhibitors on Twitter over the last few years.

The key objective of rheumatoid arthritis market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for rheumatoid arthritis market during the forecast period. Our forecast model is built on an understanding of existing market trends and the likely future opportunity for JAK inhibitors, anti-interleukins (anti-ILs) and other novel drug classes. We have provided informed estimates on the expected future sales of marketed and late stage candidates under each category, highlighting their respective shares in the overall market over the next ten years.

The research, analysis and insights presented in this market research report are backed by a deep understanding of opinions gathered from secondary research. Actual figures have been sourced and analyzed from publicly available data. Unless otherwise specified, all financial figures are presented in USD.